News

JV Bio secured the "China Biopharmaceutical Supply Chain Rock-solid Award" at the 2026 China Pharmaceutical Industry Conference, thanks to its outstanding quality control, stable delivery, and technological innovation. Backed by 108 patents and focused on core equipment such as formulation systems for antibody drugs and vaccines, JV Bio has become a solid cornerstone of the pharmaceutical supply chain.

JV Bio's "Rabies Vaccine (Chick Embryo Fibroblast) Formulation System" project won the Benchmark Project Award at the 2025 Process Industry Innovation Awards during ACHEMASIA. With multiple patented technological breakthroughs, it helped secure China's first clinical approval for a human rabies vaccine, providing an efficient, sterile, and highly reliable solution for vaccine production.